A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease
Clinical Immunology · 2024
DOI: 10.1016/j.clim.2024.110259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von M Y Hardy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Division, The Walter and Eliza Hall Institute, Parkville, Victoria, Australia; Department of Medical Biology, University of Melbourne, Par…. Hauptthemen laut MEDLINE: Celiac Disease, Glutens, HLA-DQ Antigens, Antibodies, Bispecific. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The gluten-free diet for celiac disease (CeD) is restrictive and often fails to induce complete symptom and/or mucosal disease remission. Central to CeD pathogenesis is the gluten-specific CD4+ T cell that is restricted by HLA-DQ2.5 in over 85% of CeD patients, making HLA-DQ2.5 an attractive target for suppressing gluten-dependent immunity. Recently, a novel anti-HLA-DQ2.5 antibody that specifically recognizes the complexes of HLA-DQ2.5 and multiple gluten epitopes was developed (DONQ52). OBJECTIVE: To assess the ability of DONQ52 to inhibit CeD patient-derived T-cell responses to the most immunogenic gluten peptides that encompass immunodominant T cell epitopes. METHODS: We employed an in vivo gluten challenge model in patients with CeD that affords a quantitative readout of disease-relevant gluten-specific T-cell responses. HLA-DQ2.5+ CeD patients consumed food containing wheat, barley, or rye for 3 days with collection of blood before (D1) and 6 days after (D6) commencing the challenge. Peripheral blood mononuclear cells were isolated and assessed in an interferon (IFN)-γ enzyme-linked immunosorbent spot assay (ELISpot) testing responses to gluten peptides encompassing a series of immunodominant T cell epitopes. The inhibitory effect of DONQ52 (4 or 40 μg/mL) was assessed and compared to pan-HLA-DQ blockade (SPVL3 antibody). RESULTS: In HLA-DQ2.5+ CeD patients, DONQ52 reduced T cell responses to all wheat gluten peptides to an equivalent or more effective degree than pan-HLA-DQ antibody blockade. It reduced T cell responses to a cocktail of the most immunodominant wheat epitopes by a median of 87% (IQR 72-92). Notably, DONQ52 also substantially reduced T-cell responses to dominant barley hordein and rye secalin derived peptides. DONQ52 had no effect on T-cell responses to non-gluten antigens. CONCLUSION: DONQ52 can significantly block HLA-DQ2.5-restricted T cell responses to the most highly immunogenic gluten peptides in CeD. Our findings support in vitro data that DONQ52 displays selectivity and broad cross-reactivity against multiple gluten peptide:HLA-DQ2.5 complexes. This work provides proof-of-concept multi-specific antibody blockade has the potential to meaningfully inhibit pathogenic gluten-specific T-cell responses in CeD and supports ongoing therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Division, The Walter and Eliza Hall Institute, Parkville, Victoria, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia.
- Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
- Immunology Division, The Walter and Eliza Hall Institute, Parkville, Victoria, Australia.
- Translational Research Division, Chugai Pharmaceutical Co., Ltd., Japan.
- Chugai Pharmabody Research Pty. Ltd., Singapore.
- Research Division, Chugai Pharmaceutical Co., Ltd., Japan.
Zitieren
APA
Hardy, M. Y., Henneken, L. M., Russell, A. K., Okura, Y., Mizoroki, A., Ozono, Y., Kobayashi, S., Murakami, Y., & Tye-Din, J. A. (2024). A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease. Clinical Immunology. https://doi.org/10.1016/j.clim.2024.110259
Vancouver
Hardy MY, Henneken LM, Russell AK, Okura Y, Mizoroki A, Ozono Y, et al. A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease. Clinical Immunology. 2024. doi:10.1016/j.clim.2024.110259
BibTeX
@article{Hardy2024,
author = {Hardy, M Y and Henneken, L M and Russell, A K and Okura, Y and Mizoroki, A and Ozono, Y and Kobayashi, S and Murakami, Y and Tye-Din, J A},
title = {A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease},
journal = {Clinical Immunology},
year = {2024},
doi = {10.1016/j.clim.2024.110259}
}
EUVIMED